Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 5/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 7/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 7/20 | 0.36 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.34 |
| ▸ | FURIN | P09958 | 2/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.32 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.32 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13410102 | 1.00 | FAP (0.42) | FAPSIRT1SIRT2MAP1LC3BFURIN | |
| SCHEMBL16327728 | 0.94 | FAP (0.42) | FAPSIRT1SIRT2MAP1LC3BFURIN | |
| SCHEMBL13410094 | 0.93 | SIRT2 (0.37) | FAPSIRT1SIRT2OPRK1SIRT3 | |
| SCHEMBL13401535 | 0.93 | SIRT2 (0.37) | FAPSIRT1SIRT2OPRK1SIRT3 | |
| SCHEMBL16299921 | 0.92 | FAP (0.45) | FAPSIRT1SIRT2MAP1LC3BFURIN | |
| SCHEMBL14012282 | 0.90 | FURIN (0.41) | FAPSIRT1SIRT2MAP1LC3BFURIN | |
| SCHEMBL29692594 | 0.89 | FAP (0.44) | FAPSIRT1SIRT2MAP1LC3BFURIN | |
| SCHEMBL16387730 | 0.88 | FAP (0.47) | FAPSIRT1SIRT2MAP1LC3BFURIN | |
| SCHEMBL13410103 | 0.88 | FAP (0.44) | FAPSIRT1SIRT2MAP1LC3BFURIN | |
| SCHEMBL16350292 | 0.88 | FAP (0.44) | FAPSIRT1SIRT2MAP1LC3BFURIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399403-B2 | drug-ligand conjugates that are potent cytotoxins; stabilized therapeutic agents and markers; exhibit high specificity of action, reduced toxicity, and improved stability in blood ; antitumors | MEDAREX, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399403-B2 | drug-ligand conjugates that are potent cytotoxins; stabilized therapeutic agents and markers; exhibit high specificity of action, reduced toxicity, and improved stability in blood ; antitumors | MEDAREX, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20100092496-A1 | CHEMICAL LINKERS AND CONJUGATES THEREOF | MEDAREX, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100092496-A1 | CHEMICAL LINKERS AND CONJUGATES THEREOF | MEDAREX, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-7691962-B2 | Chemical linkers and conjugates thereof | MEDAREX, INC. (US) | 2010-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100092496-A1 | CHEMICAL LINKERS AND CONJUGATES THEREOF | CLSPN, CD74, ANTXR2 | FAP 1936/4885SIRT1 1612/4885SIRT2 1758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.